152 related articles for article (PubMed ID: 31446546)
1. Radiosensitivity-related postirradiation hypothyroidism in Graves' disease patients.
Jia X; Guo K; Gao R; Yu Y; Yang A
Hormones (Athens); 2019 Sep; 18(3):267-272. PubMed ID: 31446546
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up study of radioiodine treatment of hyperthyroidism.
Metso S; Jaatinen P; Huhtala H; Luukkaala T; Oksala H; Salmi J
Clin Endocrinol (Oxf); 2004 Nov; 61(5):641-8. PubMed ID: 15521969
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of hyperthyroidism caused by Graves' disease or toxic multinodular goitre by radioiodine: over 80% cure retrospectively after one calculated dose].
Bakker SC; Zanin DE; Zweers EJ
Ned Tijdschr Geneeskd; 2002 Sep; 146(39):1837-41. PubMed ID: 12382370
[TBL] [Abstract][Full Text] [Related]
4. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
Franklyn JA; Daykin J; Holder R; Sheppard MC
QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
[TBL] [Abstract][Full Text] [Related]
5. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.
Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM
Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167
[TBL] [Abstract][Full Text] [Related]
6. [Radioiodine treatment of hyperthyroidism using a simplified dosimetric approach. Clinical results].
Giovanella L; De Palma D; Ceriani L; Vanoli P; Garancini S; Tordiglione M; Tarolo GL
Radiol Med; 2000 Dec; 100(6):480-3. PubMed ID: 11307510
[TBL] [Abstract][Full Text] [Related]
7. The development of transient hypothyroidism after iodine-131 treatment in hyperthyroid patients with Graves' disease: prevalence, mechanism and prognosis.
Aizawa Y; Yoshida K; Kaise N; Fukazawa H; Kiso Y; Sayama N; Hori H; Abe K
Clin Endocrinol (Oxf); 1997 Jan; 46(1):1-5. PubMed ID: 9059550
[TBL] [Abstract][Full Text] [Related]
8. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease.
Nygaard B; Hegedüs L; Gervil M; Hjalgrim H; Hansen BM; Søe-Jensen P; Hansen JM
J Intern Med; 1995 Dec; 238(6):491-7. PubMed ID: 9422034
[TBL] [Abstract][Full Text] [Related]
9. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
Allahabadia A; Daykin J; Sheppard MC; Gough SC; Franklyn JA
J Clin Endocrinol Metab; 2001 Aug; 86(8):3611-7. PubMed ID: 11502786
[TBL] [Abstract][Full Text] [Related]
10. 125I therapy in Graves' disease. Long-term results in 355 patients.
McDougall IR; Greig WR
Ann Intern Med; 1976 Dec; 85(6):720-3. PubMed ID: 1036667
[TBL] [Abstract][Full Text] [Related]
11. Effects of radioiodine therapy in hyperthyroidism (thyroid function, thyroid volume, Graves' ophtalmopathy, thyrotoxic heart disease).
Ursu HI; Dumitriu L; Grigorie D; Simescu M; Vaida E; Belgun M; Popovici D
Rom J Endocrinol; 1993; 31(3-4):155-63. PubMed ID: 7697064
[TBL] [Abstract][Full Text] [Related]
12. A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves' hyperthyroidism.
Marcocci C; Gianchecchi D; Masini I; Golia F; Ceccarelli C; Bracci E; Fenzi GF; Pinchera A
J Endocrinol Invest; 1990 Jun; 13(6):513-20. PubMed ID: 2258580
[TBL] [Abstract][Full Text] [Related]
13. Radioiodine therapy in Graves' disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome.
Reinhardt MJ; Brink I; Joe AY; Von Mallek D; Ezziddin S; Palmedo H; Krause TM
Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1118-24. PubMed ID: 12192554
[TBL] [Abstract][Full Text] [Related]
14. Low-dose 131I in treatment of Graves' disease.
Lowdell CP; Dobbs HJ; Spathis GS; McCready VR; Cosgrove DO; Harmer CL
J R Soc Med; 1985 Mar; 78(3):197-202. PubMed ID: 3838347
[TBL] [Abstract][Full Text] [Related]
15. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease.
Alexander EK; Larsen PR
J Clin Endocrinol Metab; 2002 Mar; 87(3):1073-7. PubMed ID: 11889166
[TBL] [Abstract][Full Text] [Related]
16. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
[TBL] [Abstract][Full Text] [Related]
17. Functional results of radioiodine therapy with a 300-Gy absorbed dose in Graves' disease.
Willemsen UF; Knesewitsch P; Kreisig T; Pickardt CR; Kirsch CM
Eur J Nucl Med; 1993 Nov; 20(11):1051-5. PubMed ID: 8287872
[TBL] [Abstract][Full Text] [Related]
18. Comparison of different thyroid committed doses in radioiodine therapy for Graves' hyperthyroidism.
Grosso M; Traino A; Boni G; Banti E; Della Porta M; Manca G; Volterrani D; Chiacchio S; AlSharif A; Borsò E; Raschillà R; Di Martino F; Mariani G
Cancer Biother Radiopharm; 2005 Apr; 20(2):218-23. PubMed ID: 15869459
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
[TBL] [Abstract][Full Text] [Related]
20. NIS mRNA expression level in resected thyroid tissue as a marker of postoperative hypothyroidism after subtotal thyroidectomy in patients with Graves' disease.
Goto A; Uchino S; Noguchi S; Wakiya S; Watanabe Y; Murakami T; Matsuura B; Onji M
Endocr J; 2008 Mar; 55(1):73-81. PubMed ID: 18187871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]